Introduction
A key aspect in the development of inhaled medications is the measurement and optimization of deposited aerosol dose. The use of imaging techniques to measure aerosol drug deposition has followed the development of more complex inhaled therapies and the invention of more advanced aerosol delivery technologies. Deposition scintigraphy techniques provide quantitative information on aerosol deposition using the radioactivity associated with an added radiopharmaceutical as an analog for drug dose. Nuclear imaging cameras can depict the deposited aerosol within the body, allowing for regional dose quantification. Deposition scintigraphy techniques have evolved along with nuclear imaging technology, and a variety of 2-dimensional and 3-dimensional techniques are now in use, some of which include anatomical imaging. These techniques have been applied with medical nebulizers, metered-dose inhalers, and powder inhalers and used in par-allel with pharmacokinetic measurements. Aerosols have also been used to deliver radiopharmaceutical probes to the lungs for physiological imaging purposes. These aerosol-based imaging techniques allow measurements of ventilation, permeability, liquid absorption, and clearance in the lungs. In some cases, these measurements have proved to be a valuable outcome measure for therapeutic development.
Techniques to Assess Aerosol Delivery
The importance of quantifying deposited aerosol dose can be appreciated by considering medications with narrow therapeutic indices, such as insulin, or with no immediate indication of clinical effect, such as an inhaled steroid. Dosing variability in aerosol drug delivery is well documented, especially in the setting of lung disease. Deposition scintigraphy can be used to quantify and optimize delivered aerosol dose and dosing variability ahead of the performance of pivotal clinical studies.
Deposition scintigraphy involves the use of either direct or indirect radiopharmaceutical labels. Technetium-99m ( 99m Tc) is often used for this labeling based on its strong imaging signal and its limited half-life (6 h). 1 Indirect labeling is performed by adding an approved 99m Tc compound, such as 99m Tc-diethylenetriamine penta-acetic or 99m
Tc-sulfur colloid, to an aerosol medication and demonstrating that the radioactivity associated with the 99m Tc distributes proportionally to the active drug content throughout a range of different aerosol sizes. 2 Direct labeling can often be performed through stannous reduction of 99m Tc before addition to the active drug. 3 If performed successfully, the 99m Tc is then bound directly to the active drug. Techniques for establishing and validating these labels are described in the literature. 4 Once a labeling method is established, a combination of the inhaled medication and the radiopharmaceutical is delivered using a clinically applicable delivery system. The radioactivity associated with 99m Tc acts as an analog for drug dose. It can be measured in the delivery system before and after delivery to determine the total delivered dose (a mass balance technique). When specific calibrations are in place, total deposited dose can also be determined directly from gamma camera images. Figure 1 includes a planar image of a lung transplant recipient performing a deposition scintigraphy study. These images provide both a qualitative picture of aerosol deposition in the lungs and a means to quantify the dose in different deposition zones. Quantification of deposited dose from gamma camera images involves a series of corrections typically including decay, background, and attenuation correction and the use of geometric mean averages of anterior and posterior images to account for the different distances between the organs and the camera. Regional dosing may be determined by simply dividing up the total planar image counts by region. Reviews of these techniques have been published as part of attempts to standardize them for multi-center use. 5 Typically ϳ148 MBq (4 mCi) of 99m Tc is added to a nebulizer for a deposition scintigraphy scan. The associated radiation exposure after inhalation depends on the efficiency of the delivery system, the physiological and radiological half-life of the radiopharmaceutical in use, and the size (age) of the patient. As an example, a 148-MBq dose of 99m Tc-sulfur colloid delivered with 20% efficiency would result in an internal dose of 29.6 MBq (0.8 mCi), which would be associated with an estimated effective dose equivalent exposure of 0.44 mSv (44 mrem) for an adult subject. 6 This is ϳ14% of yearly natural background exposure. 7 These exposure levels are low enough to allow multiple studies and pediatric applications.
Nebulizer delivery systems are the simplest to assess using deposition scintigraphy methods because the active drug is directly accessible for labeling. Many examples of deposition studies with nebulizers are available in the literature. 2, [8] [9] [10] [11] [12] These studies were instrumental in demonstrating the significant intersubject variability associated with nebulized drug delivery and contributed to the development of new and more precise delivery systems. Studies with metered-dose inhalers require on-site canister charging after drug labeling and thus pose more complications. [13] [14] [15] [16] [17] The labeling of powders presents even more substantial complications because the labeling technique must be applied without affecting the shape or size of the drug particles. This can be accomplished by incorporating the radiolabel ahead of the powder formation process 18, 19 or through careful processing of the existing powder. 20, 21 Gamma cameras have one or more imaging heads that contain a series of individual crystal or solid-state gammaray detectors. A single gamma camera head can capture a planar image similar to that shown in Figure 1 . Two gamma camera heads positioned 180°from each other can provide simultaneous anterior and posterior planar images.
Stepwise rotation of the gamma camera heads can be used to generate a series of planar images at different locations around the body that can then be processed to generate a 3-dimensional depiction of the radiopharmaceutical in the body. This process also generates a series of transverse, coronal, and sagittal views. This is the basis of singlephoton-emission computed tomography (SPECT) imaging. SPECT studies use radioisotopes similar to those described for planar scintigraphy. SPECT scans of aerosol deposition can provide exact localization of deposited dose within the 3-dimensional anatomy of the lung. In planar images, many lung structures are overlaid, making it impossible to completely differentiate between airway and alveolar deposition. SPECT imaging allows better differentiation of these structures and may allow for the isolation of specific anatomical regions. In many cases, SPECT cameras offer the option of collecting and co-registering a computed tomography (CT) or magnetic resonance imaging (MRI) scan. This can be placed onto the SPECT image to depict aerosol deposition and lung anatomy together, thus allowing for even more specific localization of aerosol deposition. However, quantification of aerosol deposition in SPECT imaging requires more complex techniques compared with those for planar imaging and longer imaging periods, and these techniques are generally used less often. [22] [23] [24] Positron emission tomography (PET) uses different radioisotopes, which emit a positively charged electron (position). Positrons travel a short distance in the body before interacting with an electron, causing annihilation and emission of 2 highenergy gamma rays in exactly opposite directions. Having 2 signals at a fixed orientation provides better signal localization and ultimately better resolution than SPECT. CT or MRI is often included with PET in the same scanner. PET has been used for aerosol imaging by a limited number of centers. 25,26 PET radiopharmaceuticals generally have shorter half-lives. The most commonly used PET radioisotope, fluorine-18, has a half-life of 110 min. A wide variety of PET radiopharmaceuticals have been produced, some including PET emitting carbon-11, which could potentially be synthesized into many active drugs. 27 MRI-based techniques have been considered for use in assessing deposited aerosol dose. These techniques offer the advantage of measurement without ionizing radiation exposure. One historic drawback of MRI in lung imaging is the imaging artifacts associated with lung expansions and contractions during the extended MRI scan time. Newer scanning techniques have largely removed these obstacles. 28 However, aerosols in these techniques need to include a contrast agent, such as gadolinium, to be detectable. Gadolinium-based deposition measurement techniques have been demonstrated in animal studies, but the required contrast amounts limit the potential for human use at this time. 29 Hyperpolarized gases are being utilized to illustrate ventilation through MRI. If a human-suitable contrast agent for aerosols could be found, this modality might allow for simultaneous imaging of ventilation and aerosol deposition.
Imaging techniques for measuring deposited doses of aerosol drugs in the lung will continue to play a role in the development of new inhaled medications and delivery devices. This includes a role in initial dose selection and in estimating population dosing variability. More sophisticated applications might include the use of multiple, tightly controlled dosing levels to determine dose-to-effect relationships. Deposition studies have, in some cases, been integrated into pharmacokinetic testing, which is a staple of medication development. 2 This combination of techniques provides a full picture of the kinetics of inhaled drug delivery. Recent attempts have been made to standardize the techniques used to perform deposition scintigraphy studies, providing a basis for application through multi-center studies. 4, 5, 24, 25, 30 This standardization may also facilitate a regulatory role for these techniques. Simple validation of sufficient dosing at sites of proposed action would seem to justify this regulatory role. Table 1 includes a summary comparison of available imaging modalities.
Aerosol-Based Physiology Measurements
Aerosolized radiopharmaceuticals are used in a variety of clinical and experimental functional nuclear imaging procedures. In these studies, radiopharmaceutical probes are used to measure specific aspects of lung physiology. Aerosol-based ventilation scans are commonly performed in nuclear medicine departments. These scans utilize nebulized 99m Tc-diethylenetriamine penta-acetic aerosols to measure lung ventilation. An injected radiopharmaceutical particle probe is then typically utilized to measure perfusion (ventilation/perfusion scan). These scans can be used to detect pulmonary emboli or ventilation/perfusion mismatching in the lungs.
Aerosol-based imaging has a long history in experimental studies of lung physiology. One common experimental application is the measurement of lung clearance. A nonabsorbable radiolabeled probe is typically delivered into the lungs. It becomes suspended in the mucus in the airways. Serial gamma camera images are collected over extended periods to measure the clearance of the mucus through mucus or cough clearance. These host-defense mechanisms are vital to protecting the lungs from inhaled pathogens and particulate. Their failure in diseases such as cystic fibrosis can lead to life-threatening opportunistic infections. Mucus clearance scans have been applied to test new medications for cystic fibrosis. In some cases, these imaging methods may provide indications of therapeutic efficacy ahead of other outcome measures. [31] [32] [33] Figure 2 shows example images depicting mucus clearance.
Radiolabeled small-molecule probes have been delivered to the lungs by aerosol to assess lung permeability. These probes can be absorbed into the bloodstream, and their rate of clearance has been used as an indication of lung inflammation and injury. Increases in the absorption rate of radiolabeled diethylenetriamine penta-acetic have been demonstrated in smokers 34 and in subjects with inflammatory diseases such as asthma. 35 Small-molecule probes have also been developed to detect changes in airway liquid absorption. In these studies, a multiprobe method is utilized. A particle probe is delivered along with a smallmolecule probe in the same aerosol. This small molecule is removed from the lungs through both absorption and mucus clearance, whereas the particle is removed only by mucus clearance. Each probe has a different radiolabel, so they can be independently tracked. The difference in the clearance rates of the probes provides an estimate of the absorption rate of the small-molecule probe. These absorptive clearance rates have been shown to be related to liquid absorption by in vitro studies and increased in the airways of patients with cystic fibrosis. Airway liquid hyperabsorption is a key aspect of cystic fibrosis lung pathophysiology that would be expected to change rapidly with a successful therapy, and this technique is being developed to rapidly screen new cystic fibrosis medications. 36,37
Limitations of Aerosol-Based Techniques
Much of the experience in measuring aerosol deposition using imaging techniques was obtained through studies of uniform solutions delivered with jet nebulizers. As inhaled drug development moves more toward the use of powders, suspensions, and complex large molecules, new labeling and validation techniques will be required. Techniques that could be applied more generally across different preparations with similar characteristics would be particularly useful.
Aerosol-based physiology techniques are ultimately limited by the methods used to deliver aerosol probes. More 
Future Developments
PET imaging provides unique opportunities for physiological lung imaging. The increased resolution of these techniques can provide local assessments that may not be possible with other modalities. A wide variety of PET probes can be produced by cyclotron. These include molecules such as carbon-11, nitrogen-13, fluorine-18, and oxygen-15. These basic molecules can be used to generate simple probes, such as 13 N-labeled ammonia or 15 O-labeled water, or more complex probes, such as active drug molecules or antibodies. Many specific PET probes have been developed to quantify aspects of physiology such as cell metabolism, tumor growth, angiogenesis, and formation of the extracellular matrix. 38-41 PET probes are commonly used to detect the increased metabolic rate associated with tumor growth. Other injected PET probes have already been used in studies of ventilation, perfusion, and inflammation. 42 However, very little work has been done with aerosol delivery. The attraction of this route is direct access to the pulmonary epithelium. As described above, PET methods provide improved resolution and can be overlaid on matching CT or MRI scans collected in the same scanner, thus allowing for exact localization. Drawbacks to PET methods include the very limited half-life of some of the positron emitters and the extensive facilities required to produce them.
Most new nuclear imaging scanners combine a functional imaging modality (SPECT or PET) with an anatomical imaging method (CT or MRI). This mixed-modality imaging allows drug doses or physiological measurements to be more exactly located. This is particularly advantageous given the complex 3-dimensional structure of the lung. Lung MRI, which was generally not considered useful in the past because of the motion artifacts associated with breathing, is becoming more common. 28, 43 This modality could potentially provide finer resolution than has previously been available through CT scans and spare patients the significant radiation burden associated with CT.
We had previously described the aerosol delivery of multiple radiolabeled probes to the lungs to measure absorptive clearance (liquid absorption) in the airways. 37 In those studies, the combination of the probes provided information that was not available with a single probe. These probes were independently resolvable because they were tagged with different radioisotopes, specifically indium-111 and 99m Tc. New imaging techniques could be designed based on a differential method such as this or a co-localization method. An intriguing example would be an imaging technique that independently depicts pathophysiology and therapeutic delivery in the lung. Consider, for example, an aerosol deposition study of an inhaled steroid that also includes a depiction of lung inflammation or a chemotherapeutic that could be localized to the site of a tumor. Delivery techniques could be tuned as part of the development process or customized to specific patients. As imaging technologies and probe developments advance, such measurements may become feasible and provide new insights into disease treatments. More precise aerosol drug delivery technologies would allow for easier and more precise application of these techniques to the lungs. 
Discussion
Rubin: Tim, that was great. I'm particularly excited about the comparison between absorption and mucus clearance. That is so powerful for our understanding of the physiology. When is it going to be ready for prime time?
Corcoran:
We published an imaging study, 1 and we published a lot of the background work as well. 2 Restrepo: There's a very nice study you should review by Lu et al. 4 They did CT [computed tomography] scans after administration of ceftazidime, and they showed how it really concentrated in different parts of the lung in different time frames and different dates. And I agree with Tim that the correlation is really variable, but it's good in certain medications. It cannot be extrapolated to every medication that gets aerosolized. I don't know the data on many different antibiotics because I think that, with these novel experiments, there are not very many in the literature to my knowledge.
Hess: I think my question follows this: there's a paper 5 I will present tomorrow morning from a group who enrolled subjects with severe acute asthma and delivered radioisotopetagged albuterol. The subjects were randomized into a nebulizer group who took it the usual way and a group who had the nebulizer in line with NIV [noninvasive ventilation]. They showed no difference in deposition or clearance between the 2 groups, but impressive differences in spirometry. I've been struggling as to how I will explain that. Maybe you can help me?
Corcoran: I brought up some of the issues we have with trying to quantify dose within the lungs, and you have to wonder if there is one treatment reaching more of the small airways, maybe a larger portion is in the medium airways. We just don't have a way to show that through these techniques. I think we're finding our limits with these techniques and reaching out to try and do things like co-register an anatomical image along with the deposition image and getting into 3D so we can really get a better idea as to what portion of the lung we're reaching. Lung dosing is probably not the story; it's dose in different areas, dose in the periphery. That would be my thought, that we're probably trying to apply a coarse technique, and it's the finer differences in deposition that really matter. That's a very interesting study.
O'Malley: I'm so curious, Dean. Which group did better in spirometry?
Hess:
The group who got their albuterol bronchodilator with NIV did better. ‡ Suggett: Nice talk, Tim. I just wonder if you would comment on the applicability of hyperpolarized helium and imaging?
Corcoran: Hyperpolarized helium-my understanding of this is fairly limited-is that it's a ventilation technique. Correct? So you're able to use the hyperpolarized helium to get a better illustration of where air ventilation is going. You would assume that there would be a nice relationship between where ventilation is and where aerosol is, but I haven't seen it used along with an aerosol technique. I may just be missing it in the literature. ‡ Suggett: No, I haven't either. I've seen it when looking at airway ventilation, but I wonder if it could be used after giving a drug just to see the effect.
